C
Causaly
AI research platform for life sciences R&D
About Causaly
Causaly builds an agentic AI research platform for life sciences R&D. It helps drug discovery and clinical development teams find and interpret biomedical evidence, turning research questions into cited, reviewable answers.
The platform combines a biomedical knowledge graph of cause-and-effect links between targets, diseases and drugs, scientific information retrieval, and a data fabric that joins public literature, full-text journals and a customer's internal data. Products include Agentic Research, Scientific Workflows, Bio Graph and its API, and Pipeline Graph. Causaly is also available inside Microsoft 365 Copilot.
Customers are pharmaceutical and biotechnology companies, such as Eisai and Innate Pharma, that use it for target identification, biomarker discovery, disease biology and indication expansion. Causaly sells enterprise software subscriptions, supported by its in-house scientists.
Source: Dealroom company dataNews
Open roles
Causaly in the London ecosystem
The Causaly office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Marathon Venture Capital
Matt Clifford
Charlie Songhurst
Nadav Rosenberg
Emerge VC
Series A7 investors entered at this stage
Pentech Ventures
European Bank for Reconstruction and Development
Index Ventures
ICONIQ Growth
Olivier Pomel
Alex Gorsky
Visionaries
Series B and later4 investors entered at this stage
ICONIQ Growth- VIVisionaries
- OPOlivier Pomel
- AGAlex Gorsky
Source: Dealroom Talent Intelligence.
See Causaly on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

